Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines

Journal of Gastroenterology

Volumn 41, Issue 2, 2006, Pages 140-150

  Miyazaki, Kaori ^a   Shibahara, Takeshi ^a   Sato, Daisuke ^a   Uchida, Kazuhiko ^a   Suzuki, Hideo ^a   Matsui, Hirofumi ^a   Yanaka, Akinori ^a   Nakahara, Akira ^a   Matsuzaki, Yasushi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

5 fluorouracil; Camptothecin; Cisplatin; Colorectal cancer; Dihydropyrimidine dehydrogenase

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYTOKINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; MITOMYCIN C; OROTATE PHOSPHORIBOSYLTRANSFERASE; PACLITAXEL; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL STRAIN CACO 2; CELL STRAIN HT29; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CACO-2 CELLS; CAMPTOTHECIN; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; CYTOKINES; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HT29 CELLS; HUMANS; INTERFERONS; LIGANDS; MITOMYCIN; OROTATE PHOSPHORIBOSYLTRANSFERASE; PACLITAXEL; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 33645286475     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-005-1733-6     Document Type: Article

References (49)

1. W Scheithauer D Depisch G Kornek J Pidlich H Rosen M Karall 1994 Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer Cancer (Phila) 73 1562-8 1:STN:280:ByuB3cjpt1M%3D
2. RM Hansen L Ryan T Anderson B Krzywda E Quebbeman A Benson 3rd et al.1996 Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer J Natl Cancer Inst 88 668-74 1:CAS:528:DyaK28XjsFWgsr0%3D 8627643
3. LB Saltz JY Douillard N Pirotta M Alakl G Gruia L Awad et al. 2001 Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: A new survival standard Oncologist 6 81-91 1:CAS:528:DC%2BD3MXhtlKjtrw%3D 11161231
4. A Villar-Grimalt MT Candel B Massuti J Lizon B Sanchez A Frau et al. 1999 A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer Br J Cancer 80 786-91 10.1038/sj.bjc.6690422 1:CAS:528:DyaK1MXjsV2ru7w%3D 10360656
5. HP Kalofonos C Nicolaides E Samantas N Mylonakis G Aravantinos MA Dimopoulos 2002 Hellenic Cooperative Oncology Group (HeCOG). A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: A Hellenic Cooperative Oncology Group (HeCOG) study Am J Clin Oncol 25 23-30 10.1097/00000421-200202000-00004 11823690
6. U Pohlen U Mansmann G Berger CT Germer U Gallkowski J Boese-Landgraf et al. 2004 Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases Anticancer Res 24 3275-82 1:CAS:528:DC%2BD2cXhtVSjsLfO 15510623
7. SD Heys O Eremin EM Ruggeri F Pein H Rainer R Oskam et al. 1995 A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma Eur J Cancer 31 19-25 10.1016/ 0959-8049(94)00360-H
8. K Okuno M Yasutomi M Kon K Hatakeyama T Muto M Kitajima et al. 1999 Intrahepatic interleukin-2 with chemotherapy for unresectable liver metastases: A randomized multicenter trial Hepatogastroenterology 46 1116-21 1:CAS:528:DyaK1MXjs1aksLg%3D 10370677
9. RB Diasio Z Lu 1994 Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy J Clin Oncol 12 2239-42 1:STN:280:ByqD2MvisVU%3D 7964937
10. MC Etienne S Cheradame JL Fischel P Formento O Dassonville N Renee et al. 1995 Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity J Clin Oncol 13 1663-70 1:STN:280:ByqA38rovVA%3D 7602356
11. PV Danenberg 1977 Thymidylate synthetase - a target enzyme in cancer chemotherapy Biochim Biophys Acta 473 73-92 1:CAS:528:DyaE1cXjtlGltw%3D%3D 145246
12. DV Santi CS McHenry H Sommer 1974 Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate Biochemistry 13 471-81 1:CAS:528:DyaE2cXnvFKjsw%3D%3D 4203910
13. CG Leichman HJ Lenz L Leichman K Danenberg J Baranda S Groshen et al. 1997 Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin J Clin Oncol 15 3223-9 1:CAS:528:DyaK2sXmslOlu7o%3D 9336359
14. A Beck MC Etienne S Cheradame JL Fischel P Formento N Renee et al. 1994 A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil Eur J Cancer 30 1517-22
15. HJ Lenz CG Leichman KD Danenberg PV Danenberg S Groshen H Cohen et al. 1996 Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival J Clin Oncol 14 176-82 1:STN:280:BymC2c%2FivFM%3D 8558194
16. GJ Peters E Laurensse A Leyva J Lankelma HM Pinedo 1986 Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes Cancer Res 46 20-8 1:CAS:528:DyaL28XmtFKgtg%3D%3D 2415245
17. GJ Peters BJ Braakhuis EA de Bruijn EJ Laurensse M van Walsum HM Pinedo 1989 Enhanced therapeutic efficacy of 5′-deoxy-5-fluorouridine in 5-fluorouracil-resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes Br J Cancer 59 327-34 1:CAS:528:DyaL1MXitVGiu7Y%3D 2522792
18. W Koizumi K Saigenji N Nakamaru I Okayasu M Kurihara 1999 Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor Oncology 56 215-22 10.1159/000011968 1:CAS:528:DyaK1MXisFGhsbc%3D 10202277
19. N Sawada T Ishikawa Y Fukase M Nishida T Yoshikubo H Ishitsuka 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013-9 1:CAS:528:DyaK1cXisFeksr4%3D 9563897
20. RB Diasio TL Beavers JT Carpenter 1988 Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity J Clin Invest 81 47-51 1:STN:280:BieD1cjptVw%3D 3335642
21. MC Etienne S Cheradame JL Fischel P Formento O Dassonville N Renee et al. 1995 Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity J Clin Oncol 13 1663-70 1:STN:280:ByqA38rovVA%3D 7602356
22. JD Laskin RM Evans HK Slocum D Burke MT Hakala 1979 Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture Cancer Res 39 383-90 1:CAS:528:DyaE1MXhtlaltbg%3D 761209
23. T Horiuchi S Suga H Sawada H Hashizume H Aoyama K Ina 1985 Basic study for the clinical application of fluoropyrimidines to cancer chemotherapy (part 1) (in Japanese with English abstract) Rinsyou Yakuri 16 475-87
24. T Masuike I Watanabe Y Takemoto 1985 Quantitative method of 5-fluorouracil and its metabolites in biological samples using high performance liquid chromatography (in Japanese with English abstract) Yakugaku Zasshi 105 1058-64 1:CAS:528:DyaL28XksFamtA%3D%3D 3835252
25. H Walczak RE Miller K Ariail B Gliniak TS Griffith M Kubin et al. 1999 Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 157-63 1:CAS:528:DyaK1MXntlSrug%3D%3D 9930862
26. AM Chinnaiyan U Prasad S Shankar DA Hamstra M Shanaiah TL Chenevert et al. 2000 Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy Proc Natl Acad Sci U S A 97 1754-9 10.1073/pnas.030545097 1:CAS:528:DC%2BD3cXhsFCrt70%3D 10677530
27. A Ashkenazi RC Pai S Fong S Leung DA Lawrence SA Marsters et al.1999 Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 155-62 1:CAS:528:DyaK1MXkslSmsbw%3D 10411544
28. K Suganuma T Kubota Y Saikawa S Abe Y Otani T Furukawa et al. 2003 Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray Cancer Sci 94 355-9 10.1111/j.1349-7006.2003.tb01446.x 1:CAS:528:DC%2BD3sXkslCns78%3D 12824904
29. H Fujiwara M Terashima T Irinoda A Takagane K Abe M Kashiwaba et al. 2002 Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR Jpn J Cancer Res 93 1342-50 1:CAS:528:DC%2BD3sXht12qtr8%3D 12495474
30. Y Ishikawa T Kubota Y Otani M Watanabe T Teramoto K Kumai et al. 999 Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice Clin Cancer Res 5 883-9
31. CA Presant W Wolf V Waluch CL Wiseman I Weitz J Shani 2000 Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy J Clin Oncol 18 255-61 1:CAS:528:DC%2BD3cXps1OrtA%3D%3D 10637237
32. Y Mizutani H Nakanishi O Yoshida M Fukushima B Bonavida T Miki 2002 Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil Eur J Cancer 38 167-76 10.1016/S0959-8049(01)00339-2 1:CAS:528:DC%2BD3MXpt1ait7Y%3D 11750847
33. M Miwa T Kojima T Naruse 2001 Serum factors attenuating the anti-tumor activity of 5-fluorouracil Cancer Biother Radiopharm 16 317-22 10.1089/ 108497801753131390 1:CAS:528:DC%2BD3MXns1ylu7k%3D 11603002
34. G Milano JL Fischel MC Etienne N Renee P Formento A Thyss et al. 1994 Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines Cancer Chemother Pharmacol 34 147-52 1:CAS:528:DyaK2cXltVKgs70%3D 8194165
35. S Lacour O Micheau A Hammann V Drouineaud J Tschopp E Solary 2003 Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells Oncogene 22 1807-16 10.1038/ sj.onc.1206127 1:CAS:528:DC%2BD3sXitlyqt7w%3D 12660816
36. E Chu JC Drake DM Koeller S Zinn CA Jamis-Dow GC Yeh et al. 1991 Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines Mol Pharmacol 39 136-43 1:CAS:528:DyaK3MXhtlGlu7o%3D 1704999
37. GJ Peters CJ van Groeningen EJ Laurensse HM Pinedo 1991 A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa Cancer (Phila) 68 1903-9 1:STN:280:By2D3crivFE%3D
38. R Fujii A Seshimo S Kameoka 2003 Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma Int J Clin Oncol 8 72-8 10.1007/s101470300013 1:CAS:528:DC%2BD3sXjt1Gju7s%3D 12720098
39. RM Evans JD Laskin MT Hakala 1981 Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil Cancer Res 41 3288-95 1:CAS:528:DyaL3MXlvVSks74%3D 6973389
40. J Ciccolini L Peillard A Evrard P Cuq C Aubert A Pelegrin 2000 Enhanced antitumor activity of 5-fluorouracil in combination with 2′-deoxyinosine in human colorectal cell lines and human colon tumor xenografts Clin Cancer Res 6 1529-35 1:CAS:528:DC%2BD3cXjtVOqtbs%3D 10778986
41. R Metzger K Danenberg CG Leichman D Salonga EL Schwartz S Wadler et al. 1998 High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil Clin Cancer Res 4 2371-6 1:CAS:528:DyaK1cXmvFyktLk%3D 9796967
42. D Salonga KD Danenberg M Johnson R Metzger S Groshen DD Tsao-Wei et al. 2000 Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin Cancer Res 6 1322-7 1:CAS:528:DC%2BD3cXjtVOqt74%3D 10778957
43. K Usuki J Saras J Waltenberger K Miyazono G Pierce A Thomason et al. 1992 Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity Biochem Biophys Res Commun 184 1311-6 10.1016/ S0006-291X(05)80025-7 1:CAS:528:DyaK38XktVWkurc%3D 1590793
44. Y Takebayashi S Akiyama S Akiba K Yamada K Miyadera T Sumizawa et al. 1996 Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma J Natl Cancer Inst 88 1110-7 1:CAS:528:DyaK28Xlslyhurc%3D 8757190
45. JL Grem KD Danenberg K Behan A Parr L Young PV Danenberg 2001 Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen Clin Cancer Res 4 999-1009
46. ME Nita O Tominaga H Nagawa T Tsuruo T Muto 1998 Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer Hepatogastroenterology 45 2117-22 1:CAS:528:DyaK1MXhtFKjtr8%3D 9951876
47. GD Heggie JP Sommadossi DS Cross WJ Huster RB Diasio 1987 Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 2203-6 1:STN:280:BiiC2MbivFE%3D 3829006
48. Y Shirota W Ichikawa H Uetake H Yamada Z Nihei K Sugihara 2002 Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer Ann Surg Oncol 9 599-603 10.1245/aso.2002.9.6.599 12095978
49. M Nishiyama W Yamamoto JS Park R Okamoto H Hanaoka H Takano 1999 Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves Clin Cancer Res 9 2620-8